Blood component administration to multiple myeloma patients treated with daratumumab: suggesting a novel approach with use of 0.1 M dithiothreitol

1. U.S. Food and Drug Administration. Daratumumab (DARZALEX). Available from https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm530249.htm. Accessed 05 February 2020. U.S. Food and Drug Administration . Daratumumab (DARZALEX) . Available from https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm530249.htm. Accessed 05 February 2020. Search in Google Scholar

2. Morandi F, Horenstein AL, Costa F, Giuliani N, Pistoia V, Malavasi F. CD38: a target for immunotherapeutic approaches in multiple myeloma. Front Immunol 2018;9:2722. Morandi F Horenstein AL Costa F Giuliani N Pistoia V Malavasi F. CD38: a target for immunotherapeutic approaches in multiple myeloma . Front Immunol 2018 ; 9 : 2722 . 10.3389/fimmu.2018.02722627987930546360 Search in Google Scholar

3. De Weers M, Tai YT, Van Der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 2011;186:1840–8. De Weers M Tai YT Van Der Veer MS , Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors . J Immunol 2011 ; 186 : 1840 – 8 . 10.4049/jimmunol.100303221187443 Search in Google Scholar

4. AABB. Mitigating the anti-CD38 interference with serological testing. AABB Assoc Bull #16-02. Bethesda, MD: AABB, 2016. AABB . Mitigating the anti-CD38 interference with serological testing. AABB Assoc Bull #16-02 . Bethesda, MD : AABB , 2016 . Search in Google Scholar

5. Chapuy CI, Nicholson RT, Aguad MD, et al. Resolving the daratumumab interference with blood compatibility testing. Transfusion 2015;55:1545–54. Chapuy CI Nicholson RT Aguad MD , Resolving the daratumumab interference with blood compatibility testing . Transfusion 2015 ; 55 : 1545 – 54 . 10.1111/trf.1306925764134 Search in Google Scholar

6. Chapuy CI, Aguad MD, Nicholson RT, et al. International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing. Transfusion. 2016;56:2964–72. Chapuy CI Aguad MD Nicholson RT , International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing . Transfusion. 2016 ; 56 : 2964 – 72 . 10.1111/trf.1378927600566 Search in Google Scholar

7. Branch DR, Muensch HA, Hian AL, Petz LD. Disulfide bonds are a requirement for Kell and Cartwright (Yta) blood group antigen integrity. Br J Haematol 1983;54:573–8. Branch DR Muensch HA Hian AL Petz LD . Disulfide bonds are a requirement for Kell and Cartwright (Yta) blood group antigen integrity . Br J Haematol 1983 ; 54 : 573 – 8 . 10.1111/j.1365-2141.1983.tb02136.x6871108 Search in Google Scholar

8. Carrel H, Sutor L, Leparc G, Doty M, Crews W. The long term storage effect of 0.2 M dithiothreitol on red cell antigen integrity in reagent red blood cells. Paper presented at the 2017 AABB Annual Meeting 2017.AABB. Carrel H Sutor L Leparc G Doty M Crews W. The long term storage effect of 0.2 M dithiothreitol on red cell antigen integrity in reagent red blood cells . Paper presented at the 2017 AABB Annual Meeting 2017.AABB . Search in Google Scholar

9. Lorenzen H, Lone Akhtar N, Nielsen M, Svendsen L, Andersen P. Thirty-three-day storage of dithiothreitol-treated red blood cells used to eliminate daratumumab interference in serological testing. Vox Sang 2018;113:686–93. Lorenzen H Lone Akhtar N Nielsen M Svendsen L Andersen P. Thirty-three-day storage of dithiothreitol-treated red blood cells used to eliminate daratumumab interference in serological testing . Vox Sang 2018 ; 113 : 686 – 93 . 10.1111/vox.1269930043984 Search in Google Scholar

10. Sigle JP, Mihm B, Suna R, Bargetzi M. Extending shelf life of dithiothreitol-treated panel RBC s to 28 days. Vox Sang 2018;113:397–9. Sigle JP Mihm B Suna R Bargetzi M. Extending shelf life of dithiothreitol-treated panel RBC s to 28 days . Vox Sang 2018 ; 113 : 397 – 9 . 10.1111/vox.1264529512161 Search in Google Scholar

11. Disbro WL. Stability guidelines for dithiothreitol-treated red blood cell reagents used for antibody detection methods in patients treated with daratumumab. Immunohematology 2017;33:105–9. Disbro WL . Stability guidelines for dithiothreitol-treated red blood cell reagents used for antibody detection methods in patients treated with daratumumab . Immunohematology 2017 ; 33 : 105 – 9 . 10.21307/immunohematology-2019-015 Search in Google Scholar

12. Hugan SL, Cooling L, Larsson VM. An evaluation of storage time for dithiothreitol-treated reagent cells. Transfusion 2017; 57:2545–6. Hugan SL Cooling L Larsson VM . An evaluation of storage time for dithiothreitol-treated reagent cells . Transfusion 2017 ; 57 : 2545 – 6 . 10.1111/trf.1424428944543 Search in Google Scholar

13. Scalea B. Phase III isatuximab trial meets primary endpoint of improving PFS in relapsed/refractory myeloma. Available at: https://www.targetedonc.com/news/phase-iii-isatuximab-trial-meets-primary-endpoint-of-improving-pfs-in-relapsedrefractory-myeloma. Accessed February 2020. Scalea B. Phase III isatuximab trial meets primary endpoint of improving PFS in relapsed/refractory myeloma . Available at: https://www.targetedonc.com/news/phase-iii-isatuximab-trial-meets-primary-endpoint-of-improving-pfs-in-relapsedrefractory-myeloma. Accessed February 2020. Search in Google Scholar

14. Setia R, Dogra M, Sachdeva P, Handoo A, Choudhary D, Agarwal A. Daratumumab (anti-CD38) interference with serological testing: an emerging challenge for blood banks in developing countries. Glob J Transfus Med 2017;2:163–5. Setia R Dogra M Sachdeva P Handoo A Choudhary D Agarwal A. Daratumumab (anti-CD38) interference with serological testing: an emerging challenge for blood banks in developing countries . Glob J Transfus Med 2017 ; 2 : 163 – 5 . 10.4103/GJTM.GJTM_42_17 Search in Google Scholar

15. Oostendorp M, Lammerts van Bueren JJ, Doshi P, et al. When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy. Transfusion 2015;55:1555–62. Oostendorp M Lammerts van Bueren JJ Doshi P , When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy . Transfusion 2015 ; 55 : 1555 – 62 . 10.1111/trf.1315025988285 Search in Google Scholar

16. Lippi G. Systematic assessment of the hemolysis index: pros and cons. Adv Clin Chem 2015;71:157–70. Lippi G. Systematic assessment of the hemolysis index: pros and cons . Adv Clin Chem 2015 ; 71 : 157 – 70 . 10.1016/bs.acc.2015.05.00226411414 Search in Google Scholar

17. Chari A, Arinsburg S, Jagannath S, et al. Blood transfusion management and transfusion-related outcomes in daratumumab-treated patients with relapsed or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 2018; 18:44–51. Chari A Arinsburg S Jagannath S , Blood transfusion management and transfusion-related outcomes in daratumumab-treated patients with relapsed or refractory multiple myeloma . Clin Lymphoma Myeloma Leuk 2018 ; 18 : 44 – 51 . 10.1016/j.clml.2017.09.00229054515 Search in Google Scholar

18. Hannon JL, Clarke G. Transfusion management of patients receiving daratumumab therapy for advanced plasma cell myeloma. Transfusion 2015;55:2770. Hannon JL Clarke G. Transfusion management of patients receiving daratumumab therapy for advanced plasma cell myeloma . Transfusion 2015 ; 55 : 2770 . 10.1111/trf.1326726559402 Search in Google Scholar

19. Tiwari AK, Aggarwal G. Daratumumab affecting the pretransfusion testing: approach to finding compatible RBC unit. Glob J Transfus Med 2017;2:166–7. Tiwari AK Aggarwal G. Daratumumab affecting the pretransfusion testing: approach to finding compatible RBC unit . Glob J Transfus Med 2017 ; 2 : 166 – 7 . 10.4103/GJTM.GJTM_44_17 Search in Google Scholar